These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 7654069)

  • 1. Acute axonal Guillain-Barré syndrome with IgG antibodies against motor axons following parenteral gangliosides.
    Illa I; Ortiz N; Gallard E; Juarez C; Grau JM; Dalakas MC
    Ann Neurol; 1995 Aug; 38(2):218-24. PubMed ID: 7654069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Antiganglioside autoantibody profiles in Guillain-Barré syndrome].
    Caudie C; Vial C; Bancel J; Petiot P; Antoine JC; Gonnaud PM
    Ann Biol Clin (Paris); 2002; 60(5):589-97. PubMed ID: 12368145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe acute axonal form of Guillain-Barré syndrome associated with IgG anti-GD1a antibodies.
    Yuki N; Yoshino H; Sato S; Shinozawa K; Miyatake T
    Muscle Nerve; 1992 Aug; 15(8):899-903. PubMed ID: 1495505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IgG anti-GM1 antibody is associated with reversible conduction failure and axonal degeneration in Guillain-Barré syndrome.
    Kuwabara S; Yuki N; Koga M; Hattori T; Matsuura D; Miyake M; Noda M
    Ann Neurol; 1998 Aug; 44(2):202-8. PubMed ID: 9708542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antiganglioside antibodies: when, which and for what].
    Gallardo E; Rojas-García R; Belvís R; Serrano-Munuera C; Ortiz E; Ortiz N; Grau J; Illa I
    Neurologia; 2001; 16(7):293-7. PubMed ID: 11485721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum antibodies to gangliosides in Guillain-Barré syndrome.
    Ilyas AA; Willison HJ; Quarles RH; Jungalwala FB; Cornblath DR; Trapp BD; Griffin DE; Griffin JW; McKhann GM
    Ann Neurol; 1988 May; 23(5):440-7. PubMed ID: 3133978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GM1/GalNAc-GD1a complex: a target for pure motor Guillain-Barre syndrome.
    Kaida K; Sonoo M; Ogawa G; Kamakura K; Ueda-Sada M; Arita M; Motoyoshi K; Kusunoki S
    Neurology; 2008 Nov; 71(21):1683-90. PubMed ID: 19015484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-glycolylneuraminic acid-containing GM1 is a new molecule for serum antibody in Guillain-Barré syndrome.
    Odaka M; Yuki N; Yoshino H; Kasama T; Handa S; Irie F; Hirabayashi Y; Suzuki A; Hirata K
    Ann Neurol; 1998 Jun; 43(6):829-34. PubMed ID: 9629854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temporal profile of anti-ganglioside antibodies and their relation to clinical parameters and treatment in Guillain-Barré syndrome.
    Press R; Matá S; Lolli F; Zhu J; Andersson T; Link H
    J Neurol Sci; 2001 Sep; 190(1-2):41-7. PubMed ID: 11574105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical correlates of high-titer IgG anti-GM1 antibodies.
    Kornberg AJ; Pestronk A; Bieser K; Ho TW; McKhann GM; Wu HS; Jiang Z
    Ann Neurol; 1994 Feb; 35(2):234-7. PubMed ID: 8109905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogenesis of axonal Guillain-Barré syndrome: hypothesis.
    Yuki N
    Muscle Nerve; 1994 Jun; 17(6):680-2. PubMed ID: 8196713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of IgG anti-GD1a antibody with severe Guillain-Barré syndrome.
    Yuki N; Yamada M; Sato S; Ohama E; Kawase Y; Ikuta F; Miyatake T
    Muscle Nerve; 1993 Jun; 16(6):642-7. PubMed ID: 8502262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-GD1a ganglioside antibodies in peripheral motor syndromes.
    Carpo M; Nobile-Orazio E; Meucci N; Gamba M; Barbieri S; Allaria S; Scarlato G
    Ann Neurol; 1996 Apr; 39(4):539-43. PubMed ID: 8619533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An anti-ganglioside antibody-secreting hybridoma induces neuropathy in mice.
    Sheikh KA; Zhang G; Gong Y; Schnaar RL; Griffin JW
    Ann Neurol; 2004 Aug; 56(2):228-39. PubMed ID: 15293275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Guillain-Barré syndrome with high titers of anti-GM2 and anti-GalNAc-GD1a antibody following cytomegalovirus hepatitis].
    Shimoya K; Ohnishi A; Hashimoto T; Yuki N
    Rinsho Shinkeigaku; 1997 Feb; 37(2):106-10. PubMed ID: 9164140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibodies to gangliosides in Guillain-Barré syndrome: specificity and relationship to clinical features.
    Gregson NA; Koblar S; Hughes RA
    Q J Med; 1993 Feb; 86(2):111-7. PubMed ID: 8464986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Measurement of antiganglioside autoantibodies by immunodot-blot assay: clinical importance in peripheral neuropathies].
    Caudie C; Vial C; Petiot P; Bancel J; Later R; Gonnaud PM
    Ann Biol Clin (Paris); 1999; 57(5):579-88. PubMed ID: 10518060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of gangliosides recognized by IgG anti-GalNAc-GD1a antibodies in bovine spinal motor neurons and motor nerves.
    Yoshino H; Ariga T; Suzuki A; Yu RK; Miyatake T
    Brain Res; 2008 Aug; 1227():216-20. PubMed ID: 18598683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical utility of measurement for anti-GM1 and anti-GQ1b antibodies].
    Tagawa Y; Matsumoto Y; Yuki N
    No To Shinkei; 1998 Sep; 50(9):849-53. PubMed ID: 9789308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antiganglioside antibodies in the pathogenesis of autoimmune neuropathies].
    Kusunoki S
    Rinsho Shinkeigaku; 1999 Jan; 39(1):93-5. PubMed ID: 10377820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.